QNRX Quoin Pharmaceuticals, Ltd.
Price Chart
Executive Summary
Lucid Capital Markets initiated coverage on Quanterix (QNRX) with a Buy rating and a $30 price target, representing a 372% upside from the current $6.36 close. The initiation comes just three days before Q1 2026 earnings on May 7, adding a high-stakes timing factor. Lucid has a 36% accuracy rate on 22 calls with a +5.8% average return, placing it below the typical coverage firm. Consensus is heavily bullish — 7 of 8 analysts rate Buy or Strong Buy, with only one Hold. The mean price target is $29.67, median $35, high $40, low $14. Lucid's $30 target is near the consensus mean but below the median. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days. EPS estimates have been revised up slightly for the current year but remain deeply negative. Insider and congressional activity is absent, but institutional positioning shows Morgan Stanley initiated a new $43.3M position, while UBS nearly exited. Short interest is elevated at 56.7% of float, signaling heavy bearish positioning. The bottom line: a high-upside initiation from a low-accuracy firm with earnings days away — high risk, high reward for aggressive traders.
Impact Score
Consensus & Targets
Consensus is strongly bullish: 2 Strong Buy, 5 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 8 analysts. The vast majority see significant upside, with only one hold rating providing any caution.
Current price: $6.36. Mean target: $29.67 (+366% upside). Median: $35. High: $40. Low: $14. Lucid's $30 target is slightly below the median but above the mean, placing it in the middle of the bullish consensus range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-04 | LUCID CAPITAL MARKETS | initiate | Buy | — |
| 2024-03-15 | Maxim Group | maintain | Buy | $4.00 |
In the past 30 days, there has been 1 upgrade (this initiation) and 0 downgrades. EPS revisions show a slight upward trend: 1 revision up for the current fiscal year in the last 7 days, and 1 in the last 30 days. However, EPS estimates remain deeply negative (-$5.55 for FY2026).
Earnings Estimates
Next earnings: May 7, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $-2.17 | $-2.17 — $-2.17 | $0.00 | ↑0 ↓0 |
| +1y | $-3.15 | $-3.15 — $-3.15 | $0.00 | ↑0 ↓0 |
| 0q | $-2.26 | $-2.26 — $-2.26 | $0.00 | ↑0 ↓0 |
| 0y | $-5.55 | $-5.55 — $-5.55 | $0.00 | ↑1 ↓0 |
Cross-Platform Signals
Insider trades: none reported. Congressional trades: none. Institutional changes: Morgan Stanley opened a new $43.3M position (bullish signal), while UBS Group AG nearly exited (-99.2% reduction, now only $7K). Short interest is 56.7% of float, extremely high — this suggests heavy bearish positioning that could fuel a short squeeze if earnings surprise positively. The institutional new buy and high short interest converge with the bullish analyst signal, but the near-exit by UBS and low firm accuracy diverge.
Actionable Insight
Aggressive traders should watch for a pre-earnings squeeze given 56.7% short interest and a new $43M institutional position. However, Lucid's low accuracy and the stock's deep losses mean this is a high-risk binary event — size accordingly.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
ANALYST-UPGRADE
| $6.36 $4.56 | ▼ −28.30% | ▼ −34.08% | $4.20 (−33.96%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.37 $4.43 | ▼ −30.46% | ▼ −33.59% | $4.20 (−34.07%) |
|
May 5, 2026
5w ago
|
ANALYST-UPGRADE
| $6.31 $4.56 | ▼ −27.73% | ▼ −32.69% | $4.20 (−33.44%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $6.48 $4.94 | ▼ −23.77% | ▼ −28.73% | $4.20 (−35.19%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $8.26 $6.46 | ▼ −21.79% | ▼ −29.41% | $4.20 (−49.15%) |
|
Mar 11, 2026
13w ago
|
8-K
| $8.09 $5.90 | ▼ −27.07% | ▼ −29.05% | $4.20 (−48.08%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $8.49 $5.74 | ▼ −32.39% | ▼ −32.91% | $4.20 (−50.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access